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ABSTRACT
Deciphering the extracellular signals that regulate SMC differentiation from stem cells is vital to
further our understanding of the pathogenesis of vascular disease and for development of cell-
based therapies and tissue engineering. Hyaluronan (HA) has emerged as an important compo-
nent of the stem cell niche, however its role during stem cell differentiation is a complicated
and inadequately deﬁned process. This study aimed to investigate the role of HA in embryonic
stem cell (ESC) differentiation toward a SMC lineage. ESCs were seeded on collagen-IV in differ-
entiation medium to generate ESC-derived SMCs (esSMCs). Differentiation coincided with
increased HA synthase (HAS) 2 expression, accumulation of extracellular HA and its assembly
into pericellular matrices. Inhibition of HA synthesis by 4-methylumbelliferone (4MU), removal
of the HA coat by hyaluronidase (HYAL) or HAS2 knockdown led to abrogation of SMC gene
expression. HA activates ERK1/2 and suppresses EGFR signaling pathways via its principle recep-
tor, CD44. EGFR inactivation coincided with increased binding to CD44, which was further aug-
mented by addition of high molecular weight (HMW)-HA either exogenously or via HAS2
overexpression through adenoviral gene transfer. HMW-HA-stimulated esSMCs displayed a func-
tional role in vascular tissue engineering ex vivo, vasculogenesis in a matrigel plug model and
SMC accumulation in neointimal lesions of vein grafts in mice. These ﬁndings demonstrate that
HAS2-induced HA synthesis and organization drives ESC-SMC differentiation. Thus, remodeling
of the HA microenvironment is a critical step in directing stem cell differentiation toward a vas-
cular lineage, highlighting HA as a potential target for treatment of vascular diseases. STEM
CELLS 2016;34:1225–1238
SIGNIFICANCE STATEMENT
Stem cell differentiation toward a smooth muscle cell (SMC) lineage plays a significant role in
the pathogenesis of vascular disease but can also offer an alternative cell source for the devel-
opment of stem cell-based tissue engineering strategies. This body of work demonstrates that
synthesis and pericellular organization of hyaluronan, an important stem cell niche component,
provide the extracellular signaling cues necessary to direct stem cell-SMC differentiation. The
possibility of controlling stem cell fate by manipulating hyaluronan (HA) within the niche
directly, or by targeting the pathways which regulate HA homeostasis, may provide significant
improvement for clinical therapy in vascular diseases.
INTRODUCTION
Embryonic stem cells (ESCs) [1, 2] are pluripo-
tent derivatives of the inner cell mass of blasto-
cysts. Owing to their dual ability for self-
renewal and differentiation into vascular line-
ages, ESCs serve as a promising source of
smooth muscle cells (SMCs) for vascular tissue
engineering, angiogenesis and vasculogenesis.
Elucidating the molecular mechanisms of SMC
differentiation from stem cells will thus be deci-
sive in developing new cell-based treatments
for vascular disease. One emerging theme is
that stem cell plasticity and fate is dependent
on their ability to actively respond to extracel-
lular cues from the surrounding microenviron-
ment or “niche” where stem cells reside. We
and others have demonstrated that ESCs can
differentiate into SMCs in response to major
functional niche components including growth
factors for example TGF-b [3] and PDGF-BB [4],
contact with supporting niche cells [5], mechan-
ical stress [6] and signals from the extracellular
matrix (ECM) [7]. More recently, hyaluronan
has been identiﬁed as a major matrix constitu-
ent of the stem cell niche [8–13].
Hyaluronan (hyaluronic acid; HA) is a
ubiquitous, hydrophilic and nonsulfated
aCardiovascular Division, BHF
Centre for Vascular
Regeneration, King’s College
London, London, United
Kingdom; bDepartment of
Physiology and
Pathophysiology, School of
Basic Medical Sciences, Key
Laboratory of Molecular
Cardiovascular Science,
Ministry of Education, Peking
University, Beijing, China
Correspondence: Qingbo Xu,
M.D., Ph.D., Cardiovascular
Division, King’s College London
BHF Centre, 125 Coldharbour
Lane, SE5 9NU London,
United Kingdom.
Telephone: 1 44 (0)20 7848
5295; Fax: 1 44 (0)20 7848
5296; e-mail:
qingbo.xu@kcl.ac.uk
Received July 7, 2015; accepted
for publication December 9,
2015; ﬁrst published online in
STEM CELLS EXPRESS February 11,
2016.
VC AlphaMed Press
1066-5099/2016/$30.00/0
http://dx.doi.org/
10.1002/stem.2328
This is an open access article
under the terms of the Creative
Commons Attribution License,
which permits use, distribution
and reproduction in any
medium, provided the original
work is properly cited.
STEM CELLS 2016;34:1225–1238 www.StemCells.com VC 2016 The Authors. STEM CELLS published by
Wiley Periodicals, Inc. on behalf of AlphaMed Press
EMBRYONIC STEM CELLS/INDUCED
PLURIPOTENT STEM CELLS
glycosaminoglycan composed of repeating disaccharide units
of D-glucoronic acid and N-acetylglucosamine. It is synthesized
at the plasma membrane via three membrane bound HA syn-
thase (HAS) isoforms (HAS1, HAS2, HAS3) [14, 15] and carries
out innumerous biological functions that are essential for,
embryogenesis [9, 16], differentiation [17–20], migration
[21–23], proliferation [20, 24, 25] and intercellular communi-
cation [26] in a variety of cell types. The wide range of biolog-
ical actions of HA derives from its versatile biosynthesis and
organization, which is regulated in a ﬂexible manner via the
three HAS isoforms which differ in intrinsic enzymic proper-
ties, HA elongation size, rate of biosynthesis and expression
patterns [27–32]. Accumulating evidence demonstrates that
HA plays a role in many facets of stem cell biology [33].
Enhanced HA synthesis during embryoid body differentiation
by ESCs is associated with epithelial-mesenchymal transition
[16]. Furthermore, differentiation of ESCs toward hematopoi-
etic cells is reliant on HA synthesis [34]. More recently, HA
synthesis and assembly into a pericellular coat was shown to
provide a protective niche for maintaining “stemness” in mes-
enchymal stem cells [8], a property which has since been
exploited in the development of HA-based hydrogel scaffolds
for tissue engineering/vascular regeneration [35–38].
However, the role of HA in the regulation of ESC-SMC dif-
ferentiation remains unclear. In the current study, we provide
novel evidence that ESC-SMC differentiation is dependent on
extracellular signals received via remodeling of the HA micro-
environment. Critically, impairment of HA synthesis and peri-
cellular organization averts ESC-SMC differentiation. We
demonstrate in vivo that in an artiﬁcial HA microenvironment,
ESC-derived SMCs (esSMCs) exhibit superior angiogenic and
vasculogenic potential. Furthermore they acquire an enhanced
migratory SMC phenotype, which promotes neointima forma-
tion in a vessel graft model. Taken together, the prospect of
regulating stem cell fate by HA manipulation may provide
new regenerative therapies for the treatment of vascular
disease.
MATERIALS AND METHODS
Detailed Methods are included in the Supporting Information.
Generation of esSMCs
esSMCs were generated as previously described [4]. Brieﬂy,
mouse ESCs were seeded on collagen IV (5 lg/ml) and differ-
entiated toward SMCs in differentiation media (DM) for up to
8 days, after which they were harvested and further analyzed.
HA Measurement
Extracellular HA secretion was evaluated using a HA binding
protein (HABP)-based ELISA kit. Pericellular and intracellular
HA was visualized using biotinylated HABP (2 lg/ml) staining
followed by incubation with Streptavidin.
HA Inhibition/Stimulation
To investigate the effects of HA deprivation on SMC differentia-
tion, esSMCs were treated with 4-methylumbelliferone (4MU)
(0.5 mmol/l) to inhibit HA synthesis, treated with hyaluronidase
(HYAL) (200lg/ml) to disrupt HA coat formation or transfected
with a speciﬁc siRNA targeting HAS2. esSMCs were cultured in
low molecular weight- (LMW-) or high molecular weight-
(HMW-) HA (200lg/ml) or transfected with a HAS2-HA adeno-
virus to investigate the effects of HA stimulation.
Ex Vivo Bioreactor
To study esSMCs migrating across the vessel wall in response
to HA stimulation, ESCs were seeded on decellularized vessels
connected to a constructed bio-rector (an ex vivo circulation
system which is driven by a pump). After 8 days of 2/
1HMW-HA stimulation, tissue engineered vessels were har-
vested and analyzed.
In Vivo Angiogenesis Assay
ESC-derived endothelial cells (esECs) were mixed equally with
2/1HA stimulated esSMCs (0.53 106) in Matrigel and sub-
cutaneously injected into TIE2-LacZ transgenic mice. One
week later the plugs were harvested and stained for SMC/EC
markers to assess the extent of vessel formation and
interaction.
Vein Graft
The procedure used for vein grafts was similar to that
described previously [39]. Brieﬂy, the vena cava vein was har-
vested from an isogenic donor and grafted between the two
ends of the carotid artery in ApoE2/2 mice. 2/1HMW-HA
stimulated esSMCs (53 105) were applied to the adventitial
side to envelope the graft. The graft was harvested after 2
weeks and analyzed for neointimal formation.
RESULTS
Extracellular HA Synthesis is Upregulated During
ESC-SMC Differentiation
Undifferentiated mouse ES cells were seeded onto collagen-
IV-coated ﬂasks and cultured in DM in the absence of leuke-
mia inhibitory factor for 1–8 days to induce SMC differentia-
tion, as previously described [4]. We found that a panel of
SMC-speciﬁc genes including a-sma, calponin, sm22-a and
smmhc were signiﬁcantly upregulated at day 8 of differentia-
tion, as conﬁrmed by RTq-PCR (Fig. 1A) and Western blot (Fig.
1B). Immunoﬂuorescence staining (Fig. 1C) also showed that
by day 8 of differentiation, ESCs were strongly positive for the
expression of a-sma, and sm22-a, conﬁrming that ESCs had
been efﬁciently differentiated toward a smooth muscle phe-
notype. Conversely, as expected, there was no apparent stain-
ing for the pluripotency markers Oct4 and Sox2, which were
observed in undifferentiated ESCs. Furthermore, phase con-
trast images showed that by day 8 of differentiation, the
spherical-like colony shape, characteristic of ESCs, had taken
on a SMC-like morphology (Fig. 1C). We deﬁned these cells as
esSMCs. Importantly, esSMCs displayed SMC marker expres-
sion comparable with mature SMCs (Supporting Information
Fig. 1A). Furthermore, esSMCs showed signiﬁcant collagen gel
contractility compared to undifferentiated ESCs (Supporting
Information Fig. 1B) and were able to contract in response to
KCl stimulation (Supporting Information Online Video 1).
Very little is known about the production of HA by stem
cells, in particular during their differentiation. To address this,
the amount of extracellular HA secreted into the conditioned
medium was collected throughout ESC-SMC differentiation
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Figure 1. ESC-SMC differentiation coincides with changes in HA synthesis and organization. ESCs were seeded on collagen IV-coated
plates (5lg/ml) and cultured in differentiation medium for up to 8 days. (A): RT-qPCR analysis demonstrated augmented levels of the
SMC markers, a-SMA, calponin, sm22-a and SMMHC over time with signiﬁcant induction at day 8 (mean6 SEM, n5 3). (B): Western
blot of SMMHC, calponin, sm22-a and a-SMA in undifferentiated ESCs (ESC) and differentiated ESCs (d4,6,8). (C): PHs show round
colony-like ESCs take on a SMC-like morphology under differentiation conditions (d4,8). Immunoﬂuorescence staining for pluripotency
markers, OCT4 and SOX2 and SMC markers a-SMA, calponin and sm22-a in undifferentiated ESCs and day 4 and 8 of differentiation. A
quantitative HA-binding protein-based kit was used to measure total (D) and de novo (E): HA secreted in medium conditioned by undif-
ferentiated ESCs and differentiated ESCs (d2,4,6,8) (mean6 SEM, n5 3). (F): Pericellular HA was visualized by immunoﬂuorescence stain-
ing with a biotinylated HA-binding probe to localize HA (green) in live cells (left panel) or by using a particle-exclusion assay (right
panel), HA-dependent pericellular coats are apparent as a clear zone between cells and formalized horse erythrocytes, arrows indicate
the cell body; arrowheads show the extent of the pericellular matrix. ESCs differentiated toward a SMC phenotype for 4 and 8 days
present increased pericellular HA coat assembly, comparable to mature SMCs (SMC). Intracellular HA was visualized by dual immunoﬂu-
orescence staining with a biotinylated HA-binding probe to localize HA (green) and a-SMA (red). Differentiation of ESCs toward SMC
phenotype is characterized by loss of intracellular HA deposition whereas mature SMCs (SMC) display signiﬁcant intracellular HA stain-
ing. Bars, 100 lm. Images and blots shown are representative of at least three separate experiments, graphs are shown as mean6 SEM
of at least three independent experiments. Analyses based on one-way ANOVA, followed by Bonferroni’s Multiple Comparison Test. *,
p< .05; **, p< .01; ***, p< .001 versus ESC. Abbreviations: ESC, embryonic stem cell; HA, hyaluronan; PHs, phase contrast images;
SMC, smooth muscle cell; RT-qPCR, quantitative reverse transcription polymerase chain reaction.
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and measured using an ELISA-type assay. Undifferentiated
ESCs synthesized very low levels of extracellular HA but within
72 hours of differentiation, total HA production was signiﬁ-
cantly upregulated (7.8-fold) and sustained over the course
of differentiation (Fig. 1D). Analysis of de novo production
revealed that the majority of HA synthesis occurs at day 3 of
differentiation and dramatically drops by day 5 and day 7 (Fig.
1E).
To further understand the role of HA in ESC-SMC differ-
entiation, supernatants were taken at different days (0, 3, 5
and 7) of differentiation in the absence or presence of 4MU,
a small molecule inhibitor of HA synthesis, which reduces
the available intracellular pool of UDP-glucuronic acid [40].
The conditioned media collected was then used to directly
culture ESCs for 48 hours. RTq-PCR analysis demonstrated
that conditioned medium from day 3 supernatant was able
to support signiﬁcant SMC marker gene induction. This
induction was ablated when culturing ESCs with 4MU-treated
media, indicating this effect was speciﬁc to HA accumulation
(Supporting Information Fig. 2). As well as extracellular HA
content, we also assessed pericellular and intracellular HA
(Fig. 1F). To monitor the extent of a pericellular HA, live
ESCs were incubated with a biotinylated HA-binding probe
and observed in undifferentiated conditions and at day 4
and 8 of differentiation. Pericellular HA staining was absent
in undifferentiated ESCs but was increasingly prominent with
differentiation (d4-8). Notably, esSMCs demonstrated signiﬁ-
cant HA staining comparable to that of mature SMCs (Fig.
1F, pericellular HA, left panel). A particle exclusion assay was
also used to verify these ﬁndings. In this assay erythrocytes
are excluded from the cell membrane by the large size and
negative charge of any pericellular HA. This is observed
under the microscope as a zone of erythrocyte exclusion sur-
rounding the cells. Whilst undifferentiated ESCs failed to
assemble a coat, day 4 and day 8 differentiated ESCs dis-
played a notable halo-like HA coat, which was comparable to
that of mature SMCs (Fig. 1F, pericellular HA, right panel).
Investigation of intracellular HA in undifferentiated ESCs
demonstrated intense HA staining which appeared to dimin-
ish with SMC differentiation. esSMCs (d8) stained positive
for the SMC marker a-sma with barely detectable HA expres-
sion. Conversely mature SMCs exhibited signiﬁcant intracellu-
lar HA staining (Fig. 1F, intracellular HA). To investigate the
relationship between intracellular HA and SMC differentia-
tion further, day 3 differentiating ESCs were ﬁxed permeabil-
ized and stained for HA and sm22-a. An extensive outgrowth
of sm22-a positive cells were observed which had migrated
and differentiated from the highly HA-stained central cellular
core (Supporting Information Fig. 3).
HA Synthesis and Pericellular Retention Drives ESC-
SMC Differentiation
The positive correlation between endogenous HA production
and ESC-SMC differentiation was further investigated by treat-
ing cells with a HA synthesis inhibitor, 4MU. As expected,
4MU treatment signiﬁcantly decreased the total amount of
HA secreted into the culture medium compared to untreated
ESCs over the differentiation time course (Fig. 2A) and was
not shown to be cytotoxic as assessed by cell viability assays
(Supporting Information Fig. 4). Critically, RT-qPCR analysis
demonstrated that 4MU treatment signiﬁcantly attenuated
the expression of the SMC markers, a-sma, calponin and
sm22-a and smmhc in esSMCs at the RNA level (Fig. 2B).
Western blot analysis conﬁrmed that the same panel of
markers were signiﬁcantly attenuated in the presence of 4MU
from day 6 of differentiation (Fig. 2C). Luciferase gene
reporter assays were performed to further determine the role
of HA synthesis. 4MU treatment signiﬁcantly decreased sm22
promoter activity in differentiating ESCs (Fig. 2D), thus sup-
porting the concept that endogenous HA synthesis has a posi-
tive effect on sm22 de novo transcription.
The role of the HA pericellular coat in ESC-SMC differen-
tiation was examined after its digestion with HYAL. Imaging of
esSMCs following incubation with a biotinylated HA-binding
probe demonstrated that HYAL treatment successfully
removed pericellular HA in mature SMCs (Supporting Informa-
tion Fig. 5) and esSMCs (Fig. 2E). RTq-PCR analysis demon-
strated that HYAL treatment suppressed induction of SMC
marker expression in esSMCs (Fig. 2F). This was also con-
ﬁrmed by Western blot (Fig. 2G). Notably, densitometry quan-
tiﬁcation revealed that whilst 4MU and HYAL treatment
signiﬁcantly suppresses induction of SMC marker expression,
4MU treatment was superior (Supporting Information Fig. 6).
Immunoﬂuorescence staining conﬁrmed that in the presence
of 4MU or HYAL, esSMCs lost a-sma, calponin and sm22-a
expression (Fig. 2H). Phase contrast imaging also revealed
that 4MU or HYAL treated esSMCs lost their SMC-like mor-
phology and retained a rounder spherical-like colony compara-
ble to undifferentiated ESCs (Fig. 2H). Collectively, these data
signify that ESC-SMC differentiation is dependent on the syn-
thesis of extracellular HA and its assembly into a pericellular
coat.
ESC-SMC Differentiation is Dependent on HAS2-
Induced HA
Having demonstrated the necessity for HA synthesis and peri-
cellular assembly during ESC-SMC differentiation, we investi-
gated the mRNA expression levels of the three HAS isoforms.
The expression of HAS1, 2 and 3 was analyzed by RT-qPCR in
undifferentiated ESCs and at days 2, 4, 6 and 8 of differentia-
tion (Fig. 3A). No signiﬁcant difference in HAS1/3 expression
was observed during differentiation, however, a prominent
induction of HAS2 mRNA expression was observed at day 4
(70-fold) and this upregulation was sustained throughout
differentiation. A direct comparison between ESCs and
esSMCs revealed that whilst HAS 1-3 levels are similar in
undifferentiated ESCs, HAS2 is the dominant synthase isoform
induced during SMC differentiation (Supporting Information
Fig. 7A). Furthermore esSMC stained positive for HAS2 and
not HAS1/3 (Supporting Information Fig. 7B). Based on these
ﬁndings, HAS2-induced HA seemed to play a vital role in the
regulation of ESC-SMC differentiation. In parallel experiments,
the mRNA expression levels of the three HYAL isoforms (HYAL
1, 2 and 3) which are responsible for the catabolism of HA
polymers were analyzed by RT-qPCR analysis. Expression of
HYAL 1 and 2 did not alter over the course of differentiation
but HYAL 3 demonstrated signiﬁcant induction between days
0 and 8 (Supporting Information Fig. 8). To test whether
HAS2-induced HA was necessary for ESC-SMC differentiation,
both overexpression and silencing strategies of HAS2 were
used. HAS2 siRNA knockdown experiments in esSMCs demon-
strated attenuated expression of the SMC markers, sm22-a
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and calponin at the RNA level (Fig. 3B) and protein level (Fig.
3C). The effects of HAS2 overexpression by adenoviral gene
transfer were also determined. Successful overexpression of
HAS2 (Fig. 2D) demonstrated enhanced expression of sm22-a
at the protein level (Fig. 3E) and induced signiﬁcant gene
expression of the all the SMC markers, a-sma, calponin,
sm22-a and smmhc at the RNA level (Fig. 3F). Furthermore,
impairment of integrin/collagen IV interaction using integrin
inhibitor G4391 resulted in inhibition of sm22-a and HAS2
expression (Fig. 3G). These data provide compelling evidence
that collagen-IV-mediated ESC-SMC differentiation is HAS2
dependent.
Figure 2. HA synthesis and pericellular organization drives ESC-smooth muscle cell (SMC) differentiation. ESCs were seeded on collagen
IV-coated plates (5lg/ml) and cultured in differentiation medium for up to 8 days with or without treatment with HA synthesis inhibitor
4MU (0.5 mmol/L) or HYAL (200lg/ml) to digest the HA coat. (A): Quantiﬁcation by a HA-binding protein-based ELISA conﬁrms that in
the presence of 4MU, accumulation of total extracellular HA synthesis is ablated during the course of ESC-SMC differentiation. (B): RT-
qPCR analysis demonstrates that a-SMA, calponin, sm22-a and SMMHC expression in esSMCs is signiﬁcantly attenuated in the presence
of 4MU. (C): Western blot of a-SMA, sm22-a, calponin and SMMHC in undifferentiated ESCs (ESC) and differentiated ESCs (d3,6,9) with
(1) and without (2) 4MU treatment. (D): Luciferase assays were performed at day 3 of ESC-SMC differentiation, showing suppressed
promotor activity for sm22-a in the presence of 4MU. RLU, relative luciferase unit. (E): Removal of pericellular HA in esSMCs by HYAL
treatment was visualized by immunoﬂuorescence staining with a biotinylated HA-binding probe to localize HA (green) in live cells (top
panel) and merged with phase contrast image (bottom panel). (F): RT-qPCR analysis demonstrates that a-SMA, calponin, sm22-a and
SMMHC expression in esSMCs is signiﬁcantly attenuated in the presence of HYAL. (G): Western blot analysis shows that a-SMA, calpo-
nin, sm22-a and SMMHC expression in esSMCs is signiﬁcantly attenuated in the presence of 4MU and to a lesser extent HYAL. For den-
sitometry quantiﬁcation see Supporting Information Figure 6. (H): Immunoﬂuorescence staining of SMC markers, a-SMA, calponin and
sm22-a in esSMCs that have been differentiated under normal differentiation conditions (control) or treated with 4MU or HYAL. PHs
demonstrate that in the presence of 4MU or HYAL, esSMCs retain colony-like morphology characteristic of undifferentiated ESCs. Bars,
100 lm. Images and blots shown are representative of at least three separate experiments, whereas graphs are shown as mean6 SEM
of at least three independent experiments. Analyses based on Student’s t test. *, p< .05; **, p< .01, versus control, or two-way
ANOVA, followed by Bonferroni’s post test. 6¼, p< .001 versus control. Abbreviations: 4MU, 4-methylumbelliferone; ESC, embryonic stem
cell; HA, hyaluronan; HYAL, hyaluronidase; PHs, phase contrast images.
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HA Dependent ESC-SMC Differentiation is Mediated
Through EGFR and ERK Signaling
Having demonstrated a role for endogenous HA synthesis, this
prompted us to explore a role for exogenous HA in ESC-SMC
differentiation. We differentiated ESCs toward SMCs under
normal differentiating conditions and in the presence of
LMW-HA or HMW-HA (Fig. 4A). In esSMCs, the expression of
all SMC markers were augmented by the addition of HMW-
HA when compared with standard differentiation medium as
evaluated by Western blot analysis. Conversely, the addition
of LMW-HA attenuated the induction of SMC marker expres-
sion in esSMCs. The ability of HMW-HA to promote differen-
tiation was consistent with our HAS data since HAS2 is
responsible for synthesizing HMW-HA only.
The HA-CD44 signaling pathway is largely associated with
EGFR and ERK signaling [18, 19, 41–43]. The role of ERK sig-
naling was investigated by pretreating ESCs with PD98059, a
potent and selective cell permeable inhibitor of MEK1/2
which blocks phosphorylation of ERK1/2. RT-qPCR analysis
demonstrated that PD98059 caused a signiﬁcant reduction in
the expression of SMC markers, a-sma, calponin, sm22-a and
smmhc in esSMCs (Fig. 4B). Inhibition of HA synthesis by
Figure 3. HAS2-induced hyaluronan is necessary for ESC-smooth muscle cell (SMC) differentiation. (A): ESCs were seeded on collagen IV-
coated plates (5lg/ml) and cultured in differentiation medium (DM) for the indicated times. RT-qPCR analysis shows expression of HAS1/
2/3 throughout differentiation time course. Over the course of differentiation HAS2 expression is signiﬁcantly augmented. ESCs were trans-
fected with HAS2 siRNA or scrambled oligonucleotide control (scramble) for 48 hours prior to further culture in DM for 72 hours. RT-qPCR
(B) and Western blot (C) show a signiﬁcant attenuation in expression of SMC markers, sm22-a and calponin. To further examine the role
of HAS2, ESCs were uninfected (ctl) or infected with an adenovirus for HAS2 overexpression (HAS2 Ad) or a null adenovirus (Null) for 48
hours then cultured in DM for a further 72 hours. (D): RT-qPCR demonstrated successful overexpression of HAS2. This resulted in signiﬁ-
cant induction of SMC gene expression as assessed by Western blot analysis (E) and RT-qPCR (F). (G): ESCs were pretreated with integrin
recognition sequence pentapeptide Glu-Arg-Gly-Asp-Ser (G4391) for 30 minutes before SMC differentiation on collagen IV-coated plates
(5lg/ml) and cultured in DM for 4 days. RGD peptide S3771 or DMSO were also used as control treatments. Western blot analysis shows
that antagonizing integrin function with G4391 resulted in inhibition of sm22-a and HAS2 expression. All blots shown are representative of
at least three separate experiments, graphs are shown as mean6 SEM of at least three independent experiments. Analyses based on Stu-
dent’s t test. *, p< .05; ***, p< .001, versus scramble/null, or one-way ANOVA, followed by Dunnett’s Multiple Comparison Test. 6¼,
p< .05; 6¼6¼, p< .01, versus ESC. Abbreviations: DMSO, dimethyl sulfoxide; ESC, embryonic stem cell.
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4MU signiﬁcantly suppressed ERK1 and ERK2 in esSMCs, indi-
cating that ERK signaling was mediated by HA (Fig. 4C). To fur-
ther investigate the role of HA-dependent activation of ERK1/
2, exogenous LMW-HA or HMW-HA was added to the culture
medium and phosphorylation of ERK1/2 was assessed over
short-term stimulations. Undifferentiated ESCs (0min) pre-
sented with low levels of pERK1/2. In the presence of LMW-
HA and HMW-HA, augmented pERK1/2 was detected at 30
Figure 4. EGFR inactivation and ERK activation mediate ESC-smooth muscle cell (SMC) differentiation. (A): Western blot of a-SMA,
sm22-a and calponin in esSMCs that have been differentiated either under normal differentiation conditions (2) or with exogenous
addition of HMW-HA (H) or LMW-HA (L) (200lg/ml). HMW-HA potentiates whereas LMW-HA attenuates SMC marker expression. (B):
RT-qPCR analysis shows the expression of the SMC markers a-SMA, calponin, sm22-a and SMMHC in esSMCs following differentiation
with or without the ERK1/2 inhibitor PD98059 (10lmol/l). (C): RT-qPCR analysis demonstrates that ERK1 and ERK2 expression in esSMCs
is signiﬁcantly attenuated in the presence of 4MU (0.5 mmol/l). (D): ESCs were stimulated with exogenous LMW-HA (L) or HMW-HA (H)
at the indicated time points. Cell lysates were analyzed by Western blotting with antibodies against pEGFR and pERK1/2. Undifferenti-
ated ESCs demonstrate basal EGFR activation which is abolished by HA stimulation. Addition of HA displays cyclic ERK1/2 phosphoryla-
tion. (E): ESCs were infected with an adenovirus for HAS2 overexpression (HAS2 Ad) or a null adenovirus (Null) for 48 hours then
differentiated in differentiation medium (DM) for a further 72 hours. Western blot analysis demonstrated that successful overexpression
of HAS2 resulted in induction of sm22-a and ERK1/2. Western blot analysis (F) and RT-qPCR analysis (G) shows the gene expression of
the SMC markers a-SMA, calponin and sm22-a in esSMCs differentiated in DM alone or in combination with the EGFR inhibitor AG1478
(10lmol/l). (H): Western blot showing Inhibition of EGFR signaling by AG1478 (10 lmol/l) has no effect on pERK1/2 at 180m differen-
tiation. (I) Western blot showing phosphorylation of ERK1/2 in esSMCs following Inhibition of HA synthesis by 4MU (0.5 mmol/l) and
Inhibition of EGFR signaling by AG1478 (10 lmol/l). 4MU suppressed pERK1/2 levels whereas AG1478 had no effect. All blots shown are
representative of at least three separate experiments, graphs are shown as mean6 SEM of at least three independent experiments.
Analyses based on Student’s t test. *, p< .05; **, p< .01, versus control. Abbreviations: 4MU, 4-methylumbelliferone; ESC, embryonic
stem cell; HA, hyaluronan.
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minutes and peaked at 180 minutes (Fig. 4D). No notable dif-
ference in ERK1/2 activation was observed between treatment
with LMW-HA or HMW-HA. Interestingly, the activation of
ERK1/2 by HA appeared to be cyclic and returned to basal
levels at 60 minutes before peak phosphorylation at 180
minutes. We investigated the regulatory role of HAS2-induced
HA synthesis in ERK1/2 activation by HAS2 adenoviral gene
transfer in esSMCs. Western blot analysis demonstrated that
prominent HAS2 induction enhanced sm22-a expression in
parallel with elevated ERK1/2 activation (Fig. 4E). Interestingly,
the detection of basal EGFR phosphorylation in undifferenti-
ated ESCs was abolished following stimulations with LMW-HA
and HMW-HA throughout the time course (Fig. 4D). To investi-
gate the role of EGFR signaling further, ESCs were differenti-
ated toward SMCs in the absence or presence of AG1478, a
tyrosine kinase inhibitor that works as a potent and selective
inhibitor of EGFR phosphorylation. Western blot (Fig. 4F) and
RT-qPCR (Fig. 4G) analysis revealed that esSMCs treated with
AG1478 demonstrate a signiﬁcant increase in expression of
SMC markers, a-sma, calponin, sm22-a and smmhc compared
to untreated esSMCs. Treatment of esSMCs with AG1478 how-
ever had no effect on early (Fig. 4H) or late (Fig. 4I) ERK1/2
phosphorylation suggesting that activation of ERK is not
dependent on EGFR signaling. Western blot analysis conﬁrmed
that upregulated ERK phosphorylation in esSMCs is restored
to basal levels displayed in undifferentiated ESCs when
treated with 4MU, demonstrating the importance of HA-
dependent activation of ERK1/2 in ESC-SMC differentiation
(Fig. 4I). Collectively, these data suggest that HA dependent
activation of ERK1/2 mediates ESC-SMC differentiation. Also,
sustained basal EGFR signaling may act as a barrier for initiat-
ing differentiation, which is overcome by HA-dependent sig-
naling. However, both HA-mediated events appear to be
independent from one another.
HAS2 Induced HA-CD44 Interaction with EGF-R Drives
ESC-SMC Differentiation
FACS analysis was used to investigate the role of cell surface
CD44 in ESC-SMC differentiation. We found that 85.4% of
esSMCs expressed CD44 in comparison to only 24.8% in undif-
ferentiated ESCs. Furthermore, in the presence of 4MU, levels
of CD44 expression in esSMCs returned to those exhibited in
undifferentiated ESCs, however, application of exogenous
LMW-HA or HMW-HA during differentiation of ESCs caused
no additional CD44 induction (Fig. 5A). Analysis of CD44 gene
expression by RT-qPCR conﬁrmed signiﬁcant upregulation dur-
ing ESC-SMC differentiation (Fig. 5B). Silencing CD44 in siRNA
transfection experiments illustrated the essential role that
CD44 plays in ESC-SMC differentiation. Successful suppression
of CD44 gene expression signiﬁcantly attenuated the induction
of SMC markers, a-sma, calponin and sm22-a in esSMCs (Fig.
5C). Following transfection of CD44 siRNA in esSMCs, phos-
phorylation of ERK1/2 was suppressed compared to scramble
control. Furthermore, the increase in pERK1/2 by LMW-HA or
HMW-HA stimulation was suppressed following CD44 silencing
(Fig. 5D). To conﬁrm the role of CD44 in early activation of
ERK1/2, ESCs were differentiated in the presence of an anti-
CD44 antibody or dimethyl nsulfoxide as a control with or
without HA treatment. After 120 minutes, induction of
pERK1/2 by LMW-HA and HMW-HA was notably reduced in
the presence of anti-CD44 antibody (Fig. 5E). Anti-CD44
immunoprecipitation followed by anti-EGFR immunoblot anal-
ysis revealed that there is an increase in the binding between
EGFR and CD44 during SMC differentiation from ESCs (Fig.
5F). This binding was shown to be regulated by HA since the
treatment of esSMCs with exogenous HMW-HA enhanced
CD44-EGFR association. However, addition of exogenous
LMW-HA failed to promote further binding (Fig. 5G). Using a
HAS2 adenovirus, we demonstrated that overexpression of
HAS2 resulted in enhanced EGFR accumulation in the CD44
immunoprecipitant compared to null transfected ECSs (Fig.
5H). CD44-EGFR association was unaltered by the ERK1/2
inhibitor PD98059, thus implying that HAS2-induced HA acti-
vation of ERK played no role in facilitating this complex which
also corroborates with earlier data (Fig. 4H-I).
HA Niche Promotes Neovascularization and Neointima
Formation
To test whether HMW-HA (HA) can also promote SMC differ-
entiation that may have functions ex vivo and in vivo, three
experimental models were used. First, a bioreactor was estab-
lished by using a mouse decellularized vessel, in which ESCs
were applied to the external side of the vessel and HA added
into the circulating medium (Supporting Information Fig. 9).
DM in the absence of HA was used as a control. Although a
small number of cells in the vessel wall, in the absence of
exogenous HA, displayed SMC positivity, the addition of HA
signiﬁcantly enhanced the number of a-SMA1 / calpo-
nin1 cells in the decellularized vessels over multiple layers
(Fig. 6A, 6B). The second model used to test the function of
HA-stimulated SMCs was in vivo vasculogenesis using a matri-
gel plug assay. We have previously reported that esECs can
form vascular tubes in vitro and in vivo [44]. esSMCs main-
tained in normal differentiation medium (control) or HMW-HA
(HA) were labeled with Vybrant cell tracker and mixed with
esECs before subcutaneous injection into a LacZ mouse. After
7 days the plug was removed and sections were stained.
Although esECs stained positive for EC marker CD31, they
exhibited a poor interaction with the Vybrant stained esSMCs
in the control experiment. However, in HA treated samples,
esSMCs displayed increased staining for the SMC marker,
sm22-a and interacted with esECs to form substantially
denser and more robust three dimensional networks of
vascular-like structures, in which some large vessels were
found (Fig. 6C, 6D). Lack of X-gal staining conﬁrmed that the
inﬁltration of cells into the plug were donor- and not host-
derived (Supporting Information Fig. 10). In the third model,
we used a mouse vein graft to compare the potential of neo-
intimal formation of esSMCs differentiated with or without
(control) exogenous HA. Both cell populations were applied to
the external side of vein grafts after isografting into apolipo-
protein E-deﬁcient mice. Grafted tissue fragments were har-
vested 2 weeks post surgery and stained with
immunoﬂuorescence smmhc to indicate SMC accumulation.
Implanted cells were also stained with Vybrant tracking dye
to discriminate between the contribution of donor and recipi-
ent cells. Grafts that had been seeded with esSMCs main-
tained in a HA microenvironment presented distinctly larger
lesions with enhanced double staining of smmhc and Vybrant
cell tracker dye compared to the control (Fig. 6E, 6F). They
also exhibited increased HA deposition (Supporting Informa-
tion Fig. 11). These results suggested that HA stimulation
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Figure 5. HA mediated CD44-EGFR interaction drives ESC-smooth muscle cell (SMC) differentiation. (A): FACS analysis showing expres-
sion of HA cell surface receptor CD44. The percentages of positive cells were calculated based on the isotype controls (gray plot). Only
24.8% of ESCs expressed CD44 (i) whereas following differentiation, esSMC expressed 85.4% (ii). Treatment with 4MU (0.5 mmol/l) dur-
ing differentiation restores CD44 levels back to that of undifferentiated ESCs (iii). During differentiation of ESCs the addition of either
exogenous LMW-HA (iv) or HMW-HA (v) treatment (200lg/ml) did not alter CD44 expression. FACS data representative for at least
three independent experiments with similar results are shown. (B): ESCs were seeded on collagen IV-coated plates (5lg/ml) and cul-
tured in DM for the indicated times. RT-qPCR analysis shows augmented gene expression of CD44 over the course of ESC-SMC differen-
tiation. (C): To further examine the role of CD44, ESCs were transfected with CD44 siRNA or scrambled oligonucleotide control
(scramble) for 48 hours prior to further culture in DM for 72 hours. RT-qPCR shows a signiﬁcant attenuation in SMC markers, a-SMA,
calponin and sm22-a. (D): ESCs were transfected with CD44 siRNA or scrambled oligonucleotide control (scramble) for 48 hours prior to
further differentiation for 72 hours in DM alone (2) or stimulation with exogenous LMW-HA (L) or HMW-HA (H) (200 lg/ml). Western
blot analysis demonstrated that knockdown of CD44 suppressed basal and HA-mediated ERK1/2 activation. (E): ESCs were preincubated
with an anti-CD44 antibody (5lg/ml) or IgG control then differentiated in the presence of either LMW-HA (L) or HMW-HA (H) (200lg/
ml) for 120m. Western blot analysis demonstrates that HA mediated pERK1/2 is retarded in the presence of anti-CD44 antibody. (F-H):
For all experiments samples were IP with anti-CD44 antibody, followed by immunoblotting with anti-EGFR antibody. Western blot analy-
sis of the precipitated complexes revealed marked binding of CD44 with EGFR during the course of differentiation (d2-d8) compared to
undifferentiated ESCs (ESC) (F). CD44-EGFR co-localisation of esSMCs (ctl) was enhanced in the presence of HMW-HA but not LMW-HA
(G). ESCs were infected with an adenovirus for HAS2 overexpression (HAS2 Ad) or a null adenovirus (Null) for 48 hours then differenti-
ated toward SMCs in the absence or presence of the ERK1/2 inhibitor PD98059 (10lmol/l). HAS2 overexpression resulted in enhanced
CD44 and EGFR association which was unaltered by ERK1/2 inhibition (H). All blots shown are representative of at least three separate
experiments, graphs are shown as mean6 SEM of at least three independent experiments. Analyses based on Student’s t test. *,
p< .05, versus scramble, or one-way ANOVA, followed by Dunnett’s Multiple Comparison Test. 6¼, p< .01, versus ESC. Abbreviations:
4MU, 4-methylumbelliferone; DM, differentiation medium; ESC, embryonic stem cell; FACS, ﬂuorescence-activated cell sorting; HA, hya-
luronan; HMW-HA, high molecular weight-hyaluronan; LMW-HA, low molecular weight-hyaluronan; IP, immunoprecipitated.
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Figure 6. HA niche promotes esSMCs neointimal accumulation and neovascularization. (A): Embryonic stem cells (53 105) were seeded
in the outer layer of a decellularized mouse thoracic aorta in a bioreactor system, either in the presence (HA) or absence (Control) of
HMW-HA in the circulating medium followed by application of shear stress. After 1 week, the vessels were harvested and embedded in
mouse liver for nitrogen freezing. The frozen sections were subjected to immunoﬂuorescence staining for the smooth muscle cell (SMC)
markers a-SMA, and calponin. Graph (B) represents mean6 SEM from three independent experiment. (C) esSMCs (53 105) maintained
in normal differentiation medium (control) or HMW-HA (HA) were mixed with esECs (53 105) then added to a Matrigel plug before sub-
cutaneous injection into a LacZ mouse. After 1 week the Matrigel plug was removed and sections were stained for EC marker CD31 or
SMC marker sm22-a (green). esSMCs were labeled with Vybrant (red) before implantation in order to be distinguished from esECs. In
control samples esECs stained positive for CD31 but exhibited weak interaction with the vybrant stained esSMCs. In HA treated samples
vybrant stained esSMCs displayed enhanced sm22-a co-localization (yellow) and interacted with esECs to form substantially denser and
more robust tube-like structures (indicated by arrows). (D): The number of tubes that were either calponin or CD31 positive were quan-
tiﬁed in ﬁve random ﬁelds of view at x10 magniﬁcation, mean6 SEM n5 6 animals. (E): Vena cava segments were surgically removed
from C57BL/6 mice under anesthesia and subsequently grafted into carotid arteries of apoE-deﬁcient recipient mice. esSMCs (53 105)
were stained with a Vybrant cell tracker dye before being seeded onto the adventitial side to envelop the vein grafts. Grafted tissue
fragments were harvested 2 weeks after surgery and stained with H&E and immunoﬂuorescence stained with SMMHC and DAPI. Vein
segments were seeded with esSMCs that were differentiated in differentiation medium in the absence of (control) or presence of
HMW-HA (HA). White squares represent the neointima, and the areas of neointimal leisions in vein grafts were quantiﬁed as described
in methods section. Graph (F) represents mean6 SEM, six animals per group. Bars, 100 lm. All analyses based on Student’s t test. *,
p< .05; **, p< .01, versus control. Abbreviations: HA, hyaluronan; H&E hematoxylin and eosin.
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resulted in a higher proportion of esSMCs to accumulate into
the graft with an enhanced SMC phenotype, and enhanced
endogenous HA secretion.
DISCUSSION
Regulation of stem cell homeostasis is mediated in part through
extrinsic cues resulting from interactions between cells and the
ECM within the niche [5, 7]. Despite being identiﬁed as a niche
component [12, 33, 45, 46], the autocrine role of endogenous
HA during stem cell differentiation is a complicated and inad-
equately deﬁned process. We report that dynamic changes in
HA homeostasis are associated with ESC-SMC differentiation.
Undifferentiated ESCs secreted relatively low amounts of extrac-
ellular HA with no evident pericellular retention. Differentiation
(at as early as day three) coincided with a dramatic increase in
HAS expression, accumulation of extracellular HA and its assem-
bly into pericellular coats. Detailed analysis of the temporal pat-
tern of HA synthesis revealed that while an accumulative
increase in HA is observed globally, following an early and size-
able induction of secreted HA (day 3), synthesis is rapidly
muted. These data suggest that an early induction of HA syn-
thesis is sufﬁcient to propagate differentiation without the
need for persistent secretion. This could be simply explained
through an autocrine feedback mechanism. Assuming endoge-
nous HA production and pericellular attachment via CD44
ensues early on, the need for additional HA synthesis would be
obsolete, providing pericellular HA and the available pool of
extracellular HA is not degraded/depleted. Nevertheless, 4MU
treatment ablated SMC differentiation at later time points and
suppressed sm22-a promoter activity in esSMCs, conﬁrming
that the presence of extracellular HA is required throughout dif-
ferentiation. In fact, only conditioned medium from day 3 dif-
ferentiated cells provided effective SMC induction when used
to culture ESCs, which was most likely a simple reﬂection of
increased HA concentration.
4MU is commonly described as a speciﬁc inhibitor of HA
synthesis, however, it was recently reported that 4MU may
impact on other GAGs, albeit to a lesser extent [47] so we
cannot rule out this phenomenon in our study. Crucially, we
demonstrate that in addition to using 4MU, speciﬁc stripping
of the HA coat using HYAL treatment attenuates SMC differen-
tiation. Mature SMCs demonstrated extensive pericellular HA
coats as previously reported [25] and likewise esSMCs exhib-
ited HA coats, albeit smaller. The magnitude of pericellular HA
accumulation has been shown to closely parallel the differen-
tiation status of cells. For example, in mesenchymal stem
cells, CD44-dependent HA coats may provide a protective
niche that support “stemness” [8]. In the current study, we
demonstrate that following HA synthesis, retention of pericel-
lular HA is a critical step for the generation of esSMCs.
Intracellular HA is now well documented in many cell
types including SMCs [48]. Recent data present a role for
intracellular HA in mediating cytoskeletal elements [41, 49,
50]. It has been proposed that the source of intracellular HA
is either degraded pericellular material [51] or from intracellu-
lar stores [52]. As far as we know, this is the ﬁrst time intra-
cellular HA has been documented in undifferentiated ESCs but
given the fact that they demonstrated no pericellular content
the latter explanation seems more plausible. In any case,
intracellular HA dissipated during differentiation but we did
not investigate its signiﬁcance. Despite observing a reduction
in HYAL2 expression, the signiﬁcant increase in HYAL3 levels
may offer a mechanism for HA degradation, however, the reg-
ulation of intracellular HA during ESC-SMC differentiation and
the role of HYALs is unclear and warrants further
investigation.
As previously reported [34], we demonstrated that all
three HAS isoforms were expressed in undifferentiated and
differentiating ESCs. Notably, HAS2 was the primary synthase
isoform induced. We were able to demonstrate that knock-
down and forced overexpression of HAS2 resulted in suppres-
sion and elevation of SMC markers, respectively, highlighting
the intrinsic role for HAS2 in ESC-SMC differentiation. Our
ﬁndings are consistent with a previous study that reports that
hESC differentiation is facilitated by HAS2-induced HA synthe-
sis [9]. However, the exact mechanism and signaling pathways
involved have remained unclear. Here we propose that
through binding to its principle receptor, CD44, HAS2-induced
HA modulates EGFR and ERK1/2 signaling.
A recent study demonstrated that the extent of CD44
expression regulates differentiation in CD341 progenitors [53].
We demonstrated that there was a prominent increase in the
expression of cell surface CD44 in esSMCs compared to undif-
ferentiated ESCs. Interestingly, endogenous HA synthesis was
found to directly augment CD44 levels since 4MU treatment
repressed CD44 induction in esSMCs. This may be explained
by the theory that inhibition of HA synthesis prevents reten-
tion at the cell surface with its synthase, or interaction with
HA receptors, CD44 and RHAMM [54]. These receptors can
readily respond to changes in amounts and size of cell surface
HA, and transmit signals intracellularly [55] which may regu-
late expression of the receptor (i.e., CD44) itself. Nonetheless,
the addition of exogenous HA did not demonstrate further
induction of CD44 expression in esSMCs possibly due to satu-
rated levels. Having demonstrated that HAS2-induced HA syn-
thesis is required for ESC-SMC differentiation, critically, using
an siRNA strategy we demonstrated that silencing CD44 atten-
uated ESC-SMC differentiation, suggesting that HA mediates
its effect through its principle receptor CD44.
The EGFR has been shown to be a regulator of “stemness”
in cancer cells. It was recently reported [56] that under normal
development constitutive EGFR becomes inactivated as cancer
stem cells differentiate and the current study supports this
model. We demonstrate that undifferentiated ESCs exhibit basal
levels of pEGFR and the addition of exogenous HA was sufﬁ-
cient to abolish basal activity at as early as 30 minutes. Further-
more, inhibition of EGFR tyrosine kinase by AG1478 resulted in
upregulation of SMC marker expression. Collectively these
results suggest that the EGFR in its active form plays a critical
role in maintaining pluripotency, supporting its role as a regula-
tor of “stemness” in ESCs. Mechanistically, loss of EGFR activa-
tion coincided with increased binding to CD44, which was
further augmented by addition of HMW-HA either exogenously
or via HAS2 overexpression. These results imply that HAS2-
induced HA mediates the functional coupling of CD44 with the
EGFR resulting in EGFR inactivation.
More recently, studies have observed that the HA-CD44
signaling pathway is largely associated with activation of ERK
[18, 42]. In addition to loss of EGFR phosphorylation, HA stim-
ulation resulted in rapid phosphorylation of ERK1/2 of a cyclic
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nature. Inhibition of SMC markers using the ERK inhibitor,
PD98059, clearly demonstrated the signiﬁcance of this path-
way in ESC-SMC differentiation. Consistent with our data, pre-
vious work has demonstrated that ERK1/2 activation
negatively regulates ESC self-renewal [57] and drives ESC-SMC
differentiation [4]. esSMCs demonstrated augmented levels of
activated ERK1/2 compared to undifferentiated ESCs. This was
shown to be dependent on endogenous HA synthesis as 4MU
treatment abolished elevated levels in esSMCs. Furthermore,
HAS2-induced HA appears to play a role since forced overex-
pression of HAS2 in esSMCs displayed an increase in ERK1/2
activation. We demonstrated that phosphorylation of ERK1/2
by HMW-HA (endogenous and exogenous) was mediated
through CD44. Silencing of CD44 attenuated early and late
ERK activation. This HA-dependent CD44-ERK signaling path-
way is however distinct from HA-dependent CD44-EGFR asso-
ciation, as inhibition of EGFR activity using AG1478 had no
effect on early and late ERK activation. When phosphorylated,
ERK may translocate to the nucleus and activate transcription
factors such as signal transducer and activator of transcription
3, which have been reported to facilitate expression of HAS2,
HA synthesis and CD44 expression [58]. Figure 7 illustrates
our proposed model for HA-mediated ESC-SMC differentiation.
The potential for using stem cells in cell-based vascular
therapy holds the promise of permanent, effective treatment
for many vascular diseases. Whether stimulating the expan-
sion of endogenous cells or transplanting cells into patients, it
is clear that engineering appropriate microenvironments that
direct vascular differentiation is paramount. Exploiting the
properties of HA has recently led to the design and
Figure 7. Illustrates our current proposed model for HA-mediated embryonic stem cell (ESC)-smooth muscle cell (SMC) differentiation.
Undifferentiated ESCs display basal EGFR phosphorylation, which plays a role in maintaining ESC pluripotency. ESCs integrin/collagen IV
interaction was associated with HAS2-dependent extracellular HA generation and its assembly into a pericellular coat. Inhibition of HA syn-
thesis by 4MU or removal of the HA coat by HYAL led to abrogation of SMC gene expression. Binding of HA to its receptor CD44 facilitates
its association with and inactivation of the EGFR and activation of ERK1/2, which may translocate to the nucleus and activate transcription
factors. Both of these pathways are independent but necessary for stem cell differentiation toward a SMC lineage. Abbreviations: 4MU, 4-
methylumbelliferone; ES, embryonic stem; HA, hyaluronan; HMW-HA, high molecular weight-hyaluronan; HYAL, hyaluronidase.
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development of HA-based hydrogel scaffolds for use in regen-
erative medicine applications [38]. In the present study, we
demonstrated that HA can promote formation of SMC layers
in a decellularized vessel scaffold, which could be useful for
creation of tissue-engineered vessels. Furthermore, esSMCs
maintained in a HMW-HA rich microenvironment were suc-
cessfully combined with esECs to form enhanced vascular-like
structures, highlighting how manipulation of the HA niche
may present an alternative and attractive strategy for promot-
ing angiogenesis/vasculogenesis. In the formation of neointi-
mal lesions of the vessel wall, lineage-tracing studies have
revealed that the differentiation of vascular stem cells also
contributes to vascular remodeling and diseases [59]. Thus,
the fate of stem cell differentiation into SMCs is a key issue
for the progression of vascular diseases. We have previously
demonstrated that adventitia stem cells actively contribute to
SMC accumulation within the neointima of vein grafts [60]. In
the current study, esSMCs applied to the external side of vein
grafts participated in lesion formation. Signiﬁcantly, we
observed that esSMCs cultured in a rich HMW-HA microenvir-
onment acquire an augmented SMC phenotype and form dis-
tinctly larger lesions, highlighting that HA-differentiated stem
cells can promote neointimal formation.
CONCLUSION
We present compelling evidence illustrating that HAS2-
induced HA synthesis and pericellular retention is essential for
ESC-SMC differentiation. Our proposed mechanism provides
new insights not only into the mode by which endogenous
HA acts as a signal integrator to facilitate ESC-SMC differentia-
tion but also by remodeling their HA niche, how stem cells
can acquire a more susceptible phenotype that promotes vas-
culogenesis and lesion formation in vein grafts. The possibility
of controlling stem cell fate by manipulating the concentra-
tion, molecular weight or organization or HA within the niche
directly, or by targeting the HA mediated pathways described
here may provide signiﬁcant improvement for clinical therapy
in vascular diseases.
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